Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystro…

Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor ...

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy December 17, ...
TipRanks on MSN

Capricor Therapeutics price target raised to $50 from $21 at B Riley

B. Riley raised the firm’s price target on Capricor Therapeutics (CAPR) to $50 from $21 and keeps a Buy rating on the shares. The clinical data ...
Parade on MSN

3 Birth Dates Attract a Lucky Break Before 2025 Ends, According to Experts

The good news is that as 2025 comes to a close, the connection between astrology and numerology provides lucky breaks to ...
BioSpaceOpinion

Absence of Bureaucracy at FDA Is Shooting Pharma in the Foot

With five CDER leaders in one year and regulatory proposals coming “by fiat,” the FDA is only making it more difficult to ...

PolyPid (PYPD) Receives a Buy from Roth MKM

Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on PolyPid today and set a price target of $9.00. According to TipRanks, Pachaiyappan is a 4-star analyst with an average return of 20.3% ...